Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Lymphokines – e.g. – interferons – interlukins – etc.
Patent
1997-07-18
2000-02-22
Draper, Garnette D.
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Lymphokines, e.g., interferons, interlukins, etc.
530402, 930141, 424 852, C07K 1454, A61K 3820
Patent
active
060281766
ABSTRACT:
This invention is directed to recombinant human IL-4 muteins numbered in accordance with wild-type IL-4 wherein the muteins comprise at least one amino acid substitution selected from the group consisting of substitutions at positions 13, 16, 81 and 89 of the wild-type IL-4, whereby the mutein binds to the IL-4R.alpha. receptor with at least greater affinity than native IL-4. The invention is further directed to recombinant human IL-4 antagonist muteins numbered in accordance with wild-type IL-4 wherein the muteins comprise substitutions R121D and Y124D in the D-helix of said wild-type IL-4; and at least one amino acid substitution selected from the group consisting of substitutions at positions 13, 16, 81 and 89 of said wild-type IL-4, whereby the mutein binds to the IL-4R.alpha. receptor with at least greater affinity than native IL-4. The invention is also directed to pharmaceutical compositions comprising individual muteins in combination with pharmaceutically acceptable carriers.
REFERENCES:
patent: 5017691 (1991-05-01), Lee et al.
patent: 5506107 (1996-04-01), Cunningham et al.
Hilton, D., et al., Cloning and characterization of a binding subunit of the interleukin-13 receptor that is also a component of the interleukin-4 receptor, PNAS-USA 93: 497-501 (1996).
Obiri, N., et al., Receptor for Interleukin 13, The Journal of Biological Chemistry--vol. 270, No. 15 (1995), pp. 8797-8804.
Matthews, D., et al., Function of the interleukin-2(IL-2) receptor .gamma.-chain in biologic responses of X-linked severe combined immunodeficient B cells to IL-2, IL-4, IL-13, and IL-15, Blood 85(1):38-42 (1995).
Walter, et al., Crystal structure of a complex between interferon-.gamma. and its soluble high-affinity receptor, Nature--vol. 376 (1995), pp. 230-235.
Kondo, M., et al., Sharing of the interleukin-2 (IL-2) receptor .gamma. chain between receptors for IL-2 and IL-4, Science--vol. 262 (1993), pp. 1874-1877.
Russell, S., et al., Interleukin-2 receptor .gamma. chain: a functional component of the interleukin-4 receptor, Science--vol. 262 (1993), pp. 1880-1883.
Economides, A., et al., Designer cytokines: targeting actions to cells of choice, Science--vol. 270 (1995), pp. 1351-1353.
Wlodawer, A., et al., Hematopoietic cytokines: similarities and differences in the structures, with implications for receptor binding, Protein Science vol. 2 (1993), pp. 1373-1382.
Kaushansky, K., et al., Hematopoietic growth factors: understanding functional diversity in structural terms, Blood--vol. 82, No. 11 (1993), pp. 3229-3240.
Kruse, N., et al., Two distinct functional sites of human interleukin-4 are identified by variants impaired in either receptor binding or receptor activation, The EMBO Journal--vol. 12, No. 13 (1993), pp. 5121-5129.
Kruse, N., et al., Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid replacement, the EMBO Journal--vol. 11, No. 9 (1992), pp. 3237-3244.
Zurawski, S., et al., Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction, The EMBO Journal--vol. 12, No. 7 (1993) pp. 2663-2670.
Aversa, G., et al., An interleukin-4 (IL-4) mutant protein inhibits both IL-4 or IL-13 induced human immunoglobulin G4 (IgG4) and IgE Synthesis and B cell proliferation: support for a common component shared by IL-4 and IL-13 receptors, J. Exp. Med. 178:2213-2218 (1993).
Maher, D.W., et al., Human interleukin-4: an immunomodulator with potential therapeutic applications, Progress in Growth Factor Research--vol. 3 (1991), pp. 43-56.
Liblau, R., et al., Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases, Immunology Today--vol. 16, No. 1 (1995), pp. 34-38.
Margolin, K., et al., Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma, Journal of Immunotherapy--vol. 15, pp. 147-153 (1994).
Schnyder, B., et al., Interleukin-4 (IL-4) and IL-13 bind to a shared heterodimeric complex on endothelial cells mediating vascular cell adhesion molecule-1 induction in the absence of the common .gamma. chain, Blood--vol. 87, No. 10 (1996), pp. 4286-4295.
Callard, R., et al., IL-4 and IL-13 receptors: are they one and the same?, Immunology Today--vol. 17, No. 3 (1996), pp. 108-110.
Morrison, B., et al., A receptor binding domain of mouse interleukin-4 defined by a solid-phase binding assay and in vitro mutagenesis, The Journal of Biological Chemistry--vol. 267, No. 17 (1992), pp. 11957-11963.
Olins, P., et al., Saturation mutagenesis of human interleukin-3, The Journal of Biological Chemistry--vol. 270, No. 40 (1995), pp. 23754-23760.
Lopez, A., et al., A human interleukin-3 analog with increased biological and binding activities, PNAS (USA)--vol. 89 (1992), pp. 11842-11846.
Lewis, C., et al., Use of a novel mutagenesis strategy, optimized residue substitution, to decrease the off-rate of an anti-gp120 antibody, Molecular Immunology--vol. 32, No. 14 (1995), pp. 1065-1072.
Savino, R., et al., Saturation mutagenesis of the human interleukin-6 receptor-binding site: implications for its three-dimensional structure, PNAS (USA)--vol. 90 (1993), pp. 4067-4071.
Savino, R., et al., Rational design of a receptor super-antagonist of human interleukin-6, The EMBO Journal--vol. 13, No. 24 (1994), pp. 5863-5870.
Lakkis, F., et al., Phe496 and Leu497 are essential for receptor binding and cytotoxic action of the murine interleukin-4 receptor targeted fusion toxin DAB.sub.389 -mIL-4, Protein Engineering--vol. 5, No. 3 (1992), pp. 241-248.
Powrie, F., et al., Cytokine regulation of T-cell function: potential for therapeutic intervention, Immunology Today--vol. 14, No. 6 (1993), pp. 270-274.
Racke, M.K., et al., Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease, J Exp. Med. (USA)--vol. 180, No. 5 (1994), pp. 1961-1966--Abstract.
Duschl, A., et al., "Antagonistic mutant proteins of interleukin-4" Behring Institute Mitteilungen--No. 6 (1995), pp. 87-94.
Morrison et al JBC 267 (17) 1992, p. 11957-63.
Muller et al J. Mol Biol 1995, v247, p. 360-72.
Greve Jeffrey M.
Roczniak Steven
Shanafelt Armen B.
Bayer Corporation
Draper Garnette D.
Jones Huw R.
LandOfFree
High-affinity interleukin-4 muteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with High-affinity interleukin-4 muteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and High-affinity interleukin-4 muteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-521521